Tango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at Guggenheim

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) had its price target lowered by Guggenheim from $18.00 to $8.00 in a report issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. Guggenheim's price objective would suggest a potential upside of 154.78% from the stock's current price.

Other research analysts have also issued reports about the company. Jefferies Financial Group started coverage on Tango Therapeutics in a research report on Wednesday, July 17th. They issued a "buy" rating and a $19.00 price objective for the company. Wedbush upped their target price on shares of Tango Therapeutics from $11.00 to $13.00 and gave the company an "outperform" rating in a research report on Thursday, August 8th. Finally, HC Wainwright reiterated a "buy" rating and issued a $13.00 target price on shares of Tango Therapeutics in a report on Monday, October 28th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tango Therapeutics currently has a consensus rating of "Buy" and an average target price of $14.29.

Tango Therapeutics Stock Performance

Shares of NASDAQ:TNGX traded down $0.10 during trading on Thursday, reaching $3.14. The stock had a trading volume of 2,323,283 shares, compared to its average volume of 868,904. The business has a fifty day moving average price of $7.75 and a 200-day moving average price of $8.35. Tango Therapeutics has a 1-year low of $2.91 and a 1-year high of $13.01. The stock has a market cap of $336.42 million, a PE ratio of -2.82 and a beta of 0.88.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.10. Tango Therapeutics had a negative return on equity of 44.73% and a negative net margin of 274.04%. The business had revenue of $19.88 million during the quarter, compared to the consensus estimate of $7.39 million. Sell-side analysts expect that Tango Therapeutics will post -1.27 earnings per share for the current year.

Insiders Place Their Bets

In other Tango Therapeutics news, insider Boxer Capital Management, Llc sold 625,000 shares of the stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $7.05, for a total value of $4,406,250.00. Following the completion of the transaction, the insider now directly owns 7,573,642 shares of the company's stock, valued at approximately $53,394,176.10. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, major shareholder Rock Ventures Iv L.P. Third sold 135,000 shares of the firm's stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $9.79, for a total transaction of $1,321,650.00. Following the transaction, the insider now owns 17,351,475 shares in the company, valued at $169,870,940.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Boxer Capital Management, Llc sold 625,000 shares of the business's stock in a transaction on Monday, October 21st. The stock was sold at an average price of $7.05, for a total value of $4,406,250.00. Following the completion of the sale, the insider now directly owns 7,573,642 shares in the company, valued at $53,394,176.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,885,400 shares of company stock valued at $15,485,582. Insiders own 6.30% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new position in Tango Therapeutics during the 2nd quarter valued at $3,836,000. Vanguard Group Inc. lifted its position in shares of Tango Therapeutics by 3.4% during the first quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company's stock worth $24,462,000 after purchasing an additional 101,673 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Tango Therapeutics by 32.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company's stock valued at $230,000 after buying an additional 7,128 shares during the last quarter. Quarry LP acquired a new position in Tango Therapeutics during the 2nd quarter valued at about $99,000. Finally, Point72 DIFC Ltd acquired a new stake in Tango Therapeutics during the 2nd quarter worth $54,000. 78.99% of the stock is owned by hedge funds and other institutional investors.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.